Smart dosing strategy could keep rheumatoid arthritis under control
NCT ID NCT06440629
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study compares two ways of managing rheumatoid arthritis in people taking adalimumab. One group gets standard care, while the other has their dose adjusted based on regular blood tests that measure drug levels and antibodies. The goal is to see if personalized dosing helps maintain disease control without flares over 18 months. About 350 adults with stable, low disease activity will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adalimumab (a tumor necrosis factor inhibitor)
What this could lead to
If successful, this approach could help people with rheumatoid arthritis maintain disease control with fewer flares by personalizing their medication dose.
What could go wrong
This is a Phase 4 study, so the drug is already approved. The main uncertainty is whether routine dose adjustments will actually reduce flares more than standard care, and some patients may need to switch therapies if antibodies develop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Betanien Hospital
Skien, 3722, Norway
-
Carol Davila University of Medicine and Pharmacy Bucharest
Bucharest, Romania
-
Diakonhjemmet sykehus
Oslo, N-0319, 0319, Norway
-
Drammen Hospital
Drammen, 3004, Norway
-
Førde Hospital Trust
Førde, 6812, Norway
-
Haugesund Rheumatism Hospital
Haugesund, 5528, Norway
-
Haukeland University Hospital
Bergen, 5009, Norway
-
Helgeland Hospital Trust
Mo i Rana, 8613, Norway
-
Hospital of Southern Norway Trust
Kristiansand, 4615, Norway
-
Humanitas Research Hospital
Milan, Italy
-
Karolinska University Hospital
Stockholm, 141 86, Sweden
-
Lillehammer Hospital for Rheumatic Diseases
Lillehammer, 2609, Norway
-
Martina Hansen's Hospital
Sandvika, Norway
-
Medical University Vienna
Vienna, A-1090, Austria
-
Nordland Hospital Trust
Bodø, 8005, Norway
-
Queen Mary
London, SW15 5PN, SW15 5PN, United Kingdom
-
Sahlgrenska Universitetssjukehuset
Gothenburg, 41345, Sweden
-
St.Olavs Hospital
Trondheim, 7030, Norway
-
Stavanger University Hospital
Stavanger, 4019, Norway
-
University Hospital of North Norway
Tromsø, 9019, Norway
-
Ålesund Hospital
Ålesund, 6017, Norway
-
Østfold Hospital Trust
Moss, 1535, Norway